Jennifer Sexton

Directora/Servicios personalizados de CAS

Bio

Como parte de los Servicios personalizados de CAS, Jennifer diseña soluciones individualizadas para los clientes aprovechando el contenido, la tecnología y los expertos en la materia de CAS para resolver los complejos retos de I+D y empresariales de los clientes. Jen se incorporó a los Servicios personalizados de CAS en 2020, tras pasar más de una década como gestora de cuentas estratégicas. Parte de su anterior función consistía en redactar e impartir formación técnica a los clientes sobre las plataformas de software CAS STN y CAS SciFinder®.

Jennifer tiene un máster en Química por la Universidad de Notre Dame. Es licenciada en Química y en Psicología por la Southwest Minnesota State University. Es miembro del Grupo de Usuarios de Información sobre Patentes (PIUG) y de la Sociedad Química Americana (ACS).

Biotechnology

Crear resiliencia y eficacia en las cadenas de suministro biotecnológicas

Descubra cómo pueden las soluciones digitales personalizadas ayudar a las empresas a crear cadenas de suministro biotecnológicas resilientes y eficaces, al tiempo que aceleran la innovación.
|Article
Read the CAS Insights article
I+D digital

AI in Pharma: Data strategies fuel successful drug repurposing

Discover how artificial intelligence in pharma can enhance drug repurposing by leveraging dark data, ensuring data diversity, and improving data quality.
|Article
Read the CAS Insights article
I+D digital

Emerging trends in global biothreat detection

Learn how emerging trends in AI are impacting CBRNE threat detection and mitigation.
|Article
Read the CAS Insights article
I+D digital

Predicting and countering chemical threats: The strategic role of data-driven technologies

Data-driven technologies play a pivotal role in swift analysis and quick response to chemical threats.
|Article
Read the CAS Insights article
I+D digital

Reducing waste through digital transformation

Learn how digital transformation is reducing waste and creating new revenue streams for companies as they repurpose waste byproducts.
|Article
Read the CAS Insights article
I+D digital

Making pharmaceutical formulation data discoverable

Pharmaceutical manufacturers are investigating ways to cultivate insights from dark formulations data, turning once-hidden knowledge into drug discoveries.
|Article
Read the CAS Insights article
I+D digital

R&D Trends: Maximizing dark data to enhance drug repurposing

As the drug repurposing market grows, pharmaceutical manufacturers are investigating ways to cultivate insights from dark formulations data, turning once hidden insights into drug repurposing innovations.
|Article
Read the CAS Insights article
I+D digital

Digital transformation in the chemical industry: Steps to a sustainable future

Digital initiatives are transforming the chemical industry, allowing for faster innovation and a sustainable future.
|Article
Read the CAS Insights article
I+D digital

Pharma data management: Revealing breakthroughs that lie in darkness

Strategies to unlock dark data in the pharmaceutical industry. Reveal data insights and accelerate innovation through digitization and knowledge management.
|Article
Read the CAS Insights article
I+D digital

Digital transformation in pharma: Improving R&D through digital solutions

Digital initiatives are transforming the pharmaceutical industry, allowing for faster drug development and expanded treatment options.
|Article
Read the CAS Insights article
I+D digital

Dark data: Uncovering hidden R&D value

Research and development teams amass huge quantities of complex data which, if exploited correctly, can be a useful information source to improve decision-making and drive innovation.
|Article
Read the CAS Insights article